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We believe that this child's illness was caused
by infection with B. burgdoiferi, or a very similar
bacterium, on the basis of the history of the erythema
chronicum migrans-like lesion following an insect bite
which preceded the recurrent febrile illness and the
serologic profIle [6]. The pattern of fever, although
recurrent, did not typify the usual descriptions of
relapsing fever [7]. Rather, this illness would have
been more accurately classifIed as a 'fever of unknown
origin'. The response to erythromycin is also consistent
with borreliosis. Furthermore, we postulate that the
amoxycillin-associated anaphylaxis and the eczematoid
rash were probably a Jarisch-Herxheimer reaction and
a chronic Borrelia dermatopathy respectively.
Fever is a relatively common symptom in pediatric
Lyme disease. Williams et al. [5] found fever (> 101°F)
to be present in approximately one-half of all patients.
In addition, the latter investigators found that the
common clinical characteristics included erythema
chronicum migrans-like rash, 'flu-like' symptoms, arth-
ritis/arthralgia, and a history of tick bite. A prolonged
and recurrent febrile illness, as witnessed for our
patient, has not been described among children. Inter-
mittent and recurrent fever is, however, a hallmark of
the relapsing fever illnesses that are caused by non-B.
burgdoiferi borreliae, but the frequency of such recur-
rences is generally 1-5; again very unlike our patient
[7]. The Borrelia serology for our patient was not
supportive of B. hermsii infection.
Fever of unknown origin has long been studied,
especially in adults, and the need for a defInition which
is based on length of undiagnosed illness has been
proposed. The addition of Lyme disease to the list
of etiologic agents possibly associated with fever of
unknown origin would only have been possible over
the last decade, when the causative bacterium was
discovered and when the laboratory diagnosis could be
more certain. Indeed, Kazanjian [8] attributed fever of
unknown origin to Lyme disease in 1 of 86 patients in
a contemporary series. Nevertheless, the clinical course
of our patient was unusual, given the especially pro-
longed course ofthe febrile illness. It is conceivable that
similar presentations may become more numerous as
experience with pediatric Lyme disease increases.
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Disseminated mucormycosis due to Absidia corymbifera in
a patient with inflammatory bowel disease
Clin Microbiol Infect 1997; 3: 268-270
Mucormycosis is a rare fungal disease principally caused
by species of the order Mucorales, family Mucoraceae
(Rhizopus, Rhizomucor, Absidia and Mucor) [1]. This
infection is usually seen in patients with certain
underlying diseases and predisposing conditions. One
of the most important features of the disease is that
diagnosis is rare ante mortem, since signs and symptoms
are non-specifIc, and the clinical course is often
fatal, especially in disseminated forms. However, the
infection is potentially curable with systemic admini-
stration of amphotericin B, agressive surgical debride-
ment, and control of the underlying disease. We report
a disseminated form ofmucormycosis caused by Absidia
corymbifera, in a patient under treatment with steroids
and cytostatic agents because of inflammatory bowel
disease.
A 60-year-old man was admitted to the hospital
on 12 January 1995, following a 14-day history of
Letters to the Editors
weight loss, abdominal colic, vomltmg and bloody
diarrhea. A diagnosis of inflammatory bowel disease
was made on the basis of the histopathologic findings
in an intestinal mucosal biopsy, and treatment with
total parenteral nutrition, oral sulfasalazine (3 g/day),
intravenous methylprednisolone (20 mg t.i.d.), and oral
6-mercaptopurine (200 mg/day) was initiated.
Eleven days after his hospital discharge he was
readmitted with high fever, nausea and vomiting,
diarrhea and continuous pain in his right flank. The
white blood cell (WEC) count was 5900/mm3 (43%
neutrophils, 55% lymphocytes and 2% monocytes), but
4 days later the WBC count was 1400/mm3 (65%
neutrophils, 31% lymphocytes and 4% monocytes),
and there was a significant rise in the blood aspartate
aminotransferase, alanine aminotransferase, alkaline
phosphatase, y-glutamyltransferase, bilirubin and lactate
dehydrogenase (LDH) levels. Repeated cultures of
urine, stool and blood samples were negative. An
abdominal CT scan showed enlargement of the right
kidney with multiple hypodense areas inside, but
microscopic examination and culture of material
obtained by percutaneous puncture failed to yield
any pathogen. Empirical treatment with ceftazidime,
amikacin, vancomycin and metronidazole was started
but fever persisted. Two weeks later the patient
presented increased abdominal tenderness and severe
bloody diarrhea, and he underwent laparotomy. The
whole colon was inflamed, the right kidney was
enlarged, and there were small amounts of free
peritoneal fluid. An elective nephrectomy and a total
colectomy were performed.
Histopathologic study of the right kidney revealed
large areas of necrosis and a chronic inflammatory
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infiltrate of lymphocytes and plasma and giant cells.
The blood vessels of the right kidney and mesocolon
were thrombosed, and the vessel walls were invaded by
numerous hyphae; these were broad and non-septate
and branched at right angles. Culture of the surgical
specimen of the right kidney yielded a rapidly growing
fungus identified as Absidia corymbifera.
Treatment was changed to systemic amphotericin
B at low doses (0.7 mg/kg/day), because renal function
began to deteriorate. However, his state was com-
plicated by multi-organ failure and he died 8 days later.
An autopsy was not performed.
In a recent autopsy-based Spanish study, post-
mortem examination showed evidence of fungal
infections in 3.5% (22/632) of all autopsies recorded
between 1986 and 1993. Only one instance ofinfection
by zygomycetes was encountered (1/22) [2]. The true
incidence of this infection is difficult to estimate. The
problem with diagnosis arises in growing the fungus for
speciation. Even when adequate biopsy specimens are
obtained, the fungus is often non-viable within the
necrotic material, and diagnosis rests on histologic
demonstration of fungal elements, making accurate
speciation impossible without specialized inmuno-
chemical stains. The first descriptions of a particular
Absidia corymbifera strain as a human pathogen were
made in the 19th century by Fiibringer [3] and Podack.
Since then, there have been no more than 15 cases well
documented in the literature reviewed (Table 1). There
are four cases reported in patients with hematologic
malignancies [4-7], four in HIV patients [8-11],
another one in a drug abuser [12], one following a
kidney transplant [13], one in a patient with metastatic
carcinoma [14], and two that did not present any
Table 1 Clinical features of reported cases of infections caused by Absidia corymbifera
Ref./year Age/Sex Underlying disease Clinical form Therapy Outcome
13/1972 NA Kjdney transplant Rhinocerebral NA Cured
6/1979 55/M Acute leukemia Cutaneous Surgery + Amphotericin B Died
12/1982 27/M Drug abuser Rhinocerebral Not antifungal Died
14/1982 50/F Metastatic carcinoma Disseminated Not antifungal Died
4/1987 54/F Acute leukemia Rhinocerebral Amphotericin B Died
4/1987 41/F Lymphoma Rhinocerebral Amphotericin B Died
5/1988 49/F Acute leukemia Disseminated Amphotericin B Died
15/1988 56/M Healthy Rhinocerebral Amphotericin B Died
16/1988 45/M Healthy Pulmonary Surgery + Amphotericin B Cured
9/1989 29/M AIDS Renal Amphotericin B Cured
10/1990 35/M AIDS Pulmonary Amphotericin B Died
11/1992 35/M AIDS Cutaneous NA Cured
8/1993 24/M AIDS Renal Amphotericin B Cured
7/1995 NA Acute leukemia Cutaneous NA Cured
PR/1996 60/M Inflammatory bowel disease Disseminated Amphotericin B Died
NA=not available; PR=present report.
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predisposing factors [15,16]. The most common forms
of presentation have been rhinocerebral, pulmonary,
cutaneous and disseminated forms. Characteristically,
there is a high mortality rate; in fact, we only found
three reports of survival.
Systemic amphotericin B is the drug of choice. It
is recommended to start with maximal doses from the
beginning, so this mucormycosis would be an excellent
indication for lipid-based preparations. In our case we
started with a dose of 0.7 mg/kg/day because renal
function was deteriorating. But this was obviously
inadequate, as the patient state deteriorated, and he
finally died before we could increase the total dosage
of antifungal. Species of Absidia have been shown to be
susceptible in vitro to most antifungal agents, and there
is a report of three patients with mucormycosis
infection who have been effectively treated with
fluconazole [17].
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Subinhibitory concentrations of gentamicin reduce
production of listeriolysin. the main virulence factor of
Listeria monocytogenes
Clin Microbiol Infect 1997; 3: 270-272
The facultatively intracellular Gram-positive rod Listeria
monocytogenes is the causative agent of severe infections
in humans and animals, e.g. sepsis and meningo-
encephalitis. The treatment of choice is ampicillin in
combination with gentamicin [1]. Because of poor
penetration through the blood-brain barrier and into
the cytoplasm ofcells where the listeriae multiply, these
antibiotics are likely to reach concentrations below the
levels obtained in the blood at the site of infection.
Certain antibiotics are able to retard growth of
bacteria at concentrations below the minimal inhibi-
tory concentration assessed visually. In addition, some
antibiotics are capable of selectively inhibiting the
production of virulence factors by pathogenic bacteria
[2]. Ampicillin has recently been shown to reduce the
production of listeriolysin [3]. Listeriolysin is an
essential virulence factor of L. monocytogenes because
it enables the bacterium to reach the cytoplasm of
infected cells, and to start multiplication [4].
Inhibition of the production of listeriolysin could
also contribute to the therapeutic action of gentamicin
on human listeriosis. Therefore, the effect of genta-
